Companies with a high P/E ratio are typically growth stocks. About 29,152 shares traded. It has underperformed by 5.63% the S&P500. Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. (NASDAQ:RVNC) is a huge mover today! The shares were sold at an average price of $23.58, for a total value of $179,208.00. (NASDAQ:RVNC). New York-based Tower Cap Ltd Llc (Trc) has invested 0% in Revance Therapeutics, Inc. Along with these its last twelve month performance is stands at 46.07% while moved 8.79% for the past six months according to Finviz reported data. We have $37.50 PT which if reached, will make NASDAQ:RVNC worth $95.76M more.
Investors sentiment increased to 1.96 in 2017 Q2. Its up 0.99, from 0.97 in 2017Q1. It is positive, as 36 investors sold SM Energy Company shares while 59 reduced holdings. Its down 1.99% from 3.64M shares previously. Lasalle Investment Management Securities Llc sold 164,663 shares as Crown Castle Intl Corp (CCI)'s stock rose 11.44%. Three Peaks Mngmt Limited Liability owns 175,863 shares for 0.43% of their portfolio. Alps Advsr Inc invested in 27,324 shares. Swiss Bancorp owns 166,750 shares. 25,333 were reported by Rhumbline Advisers. Crestwood Advisors Gp Ltd Com holds 1.36% or 158,937 shares in its portfolio. Moreover, Creative Planning has 0% invested in Revance Therapeutics, Inc. Thrivent Financial For Lutherans reported 22,558 shares stake. (NASDAQ:RVNC). Great West Life Assurance Company Can holds 2,553 shares or 0% of its portfolio.
SM Energy Company, an independent energy company, engages in the acquisition, exploration, development, and production of crude oil and condensate, natural gas, and natural gas liquids in onshore North America. It primarily has activities in the South Texas and Gulf Coast, Rocky Mountain, and Permian regions. It now has negative earnings. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Therefore 65% are positive. (NASDAQ:RVNC) on Tuesday, October 24 with "Buy" rating. The Stock has YTD (year to date) performance of 67.87 percent. Finally, Parametric Portfolio Associates LLC increased its stake in Revance Therapeutics by 5.9% in the first quarter. The company was maintained on Thursday, June 8 by Aegis Capital.
Lasalle Investment Management Securities Llc increased American Campus Communities Inc (NYSE:ACC) stake by 225,127 shares to 4.40M valued at $207.91 million in 2017Q2. The rating was maintained by Suntrust Robinson with "Buy" on Tuesday, June 14. The firm's market capitalization is $714.44 million. The firm earned "Neutral" rating on Wednesday, June 21 by Seaport Global.
More notable recent Revance Therapeutics, Inc. The High end of the forecast is $-0.89 per share, while the Low end is $-1.02 per share. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.06). Granite Investment Ptnrs Ltd Liability Corporation has invested 0.12% of its portfolio in Revance Therapeutics, Inc. The company has market cap of $1.06 billion. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is now in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. (NASDAQ:RVNC). Tiaa Cref Inv Mgmt invested 0% of its portfolio in Revance Therapeutics, Inc. Revance Therapeutics has $5000 highest and $22 lowest target. A total of 8.11 Million shares exchanged at hands and its Average Volume (3 months) is 192.75 Million. Zacks Investment Research downgraded shares of Revance Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 12th. (NASDAQ:RVNC) has "Buy" rating given on Thursday, November 2 by SunTrust. The stock has "Buy" rating by Cantor Fitzgerald on Thursday, November 16.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 2nd. The firm has "Buy" rating given on Wednesday, March 23 by SunTrust. The company was initiated on Monday, November 27 by Barclays Capital. Guggenheim initiated the stock with "Buy" rating in Monday, November 23 report.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.